Financial Performance - The company's operating revenue for the reporting period was approximately CNY 790.49 million, showing a slight increase compared to the previous quarter's CNY 761.23 million[5]. - Net profit attributable to shareholders was CNY 86.95 million, a decrease from CNY 97.07 million in the previous quarter[5]. - The net cash flow from operating activities reached CNY 235.42 million, up from CNY 206.36 million in the previous quarter[5]. - The company's total revenue for 2023 reached ¥3,102,580,918.31, representing a year-on-year increase of 3.10% compared to ¥3,009,229,135.39 in 2022[80]. - The cost of sales increased by 8.58% to ¥1,944,485,343.22 from ¥1,790,843,728.24 in the previous year[80]. - The net cash flow from operating activities decreased by 5.25% to ¥658,652,838.62, down from ¥695,121,586.16 in 2022[80]. - The revenue from the nutrition and health products segment was ¥3,023,706,681.23, accounting for 97.46% of total revenue, with a year-on-year growth of 3.02%[86]. - The sales volume of nutrition and health products decreased by 12.06% to 3,199,290.53 kg from 3,637,987.91 kg in 2022[87]. - The gross profit margin for the nutrition and health products segment was 37.21%, reflecting a decrease of 3.02% compared to the previous year[86]. - The company reported a significant decline in revenue from its vitamin segment, with a decrease of 52.20% year-over-year[129]. Market Trends and Industry Insights - The global health consumption market size reached USD 321.9 billion in 2023, with a year-on-year growth of 5.81%[15]. - The feed additive industry in China saw a total output value of CNY 1,223.42 billion in 2023, growing by 6.5% year-on-year[19]. - The vitamin production capacity in China has entered a new expansion phase, with the country now accounting for over 70% of global vitamin production[44]. - The market for DHA derived from algae oil is rapidly growing, with advantages in food safety and quality control[47]. Product Development and Innovation - The company achieved record sales of coenzyme Q10 raw materials, with production and sales hitting historical highs[34]. - The company is expanding its product line with new projects, including an annual production of 100 tons of adenosylmethionine and 1,000 tons of astaxanthin, which are nearing completion[34]. - The company has a strong research and innovation capability, continuously optimizing production processes to reduce costs and improve product efficacy and safety[45]. - The company utilizes biocatalysis technology for the production of NMN raw materials, ensuring advanced and reliable production processes[46]. - The company is focusing on technological innovation and product development to strengthen its market competitiveness[54]. Sales and Distribution - The company employs a direct sales model combined with distribution, with no restrictions on the number of distributors or sales areas[38]. - The company reported a total sales revenue of 493,554,910.90 CNY from its top distributor, accounting for 15.91% of total sales[40]. - The online sales of nutrition and health products increased by 16.55% to ¥992,397,839.82, representing 31.99% of total revenue[86]. - The company has established 9 health food sales stores in major business districts in Singapore, utilizing a direct sales model[60]. Research and Development - The company held 182 authorized patents as of December 31, 2023, including 176 in China and 6 in the United States[68]. - The company's total R&D expenditure was CNY 66,594,017.88, representing a decrease of 7.33% from CNY 71,857,719.17 in the previous year[113]. - The number of R&D personnel increased by 15.42% to 232, with the proportion of R&D personnel in the company rising to 10.91%[93]. - Research and development expenses decreased by 19.01% to ¥58,198,995.12 from ¥71,857,719.17 in the previous year[92]. Financial Position and Cash Flow - The company's total operating cash inflow for 2023 was CNY 3,188,829,940.57, a slight increase of 0.33% compared to CNY 3,178,349,626.47 in 2022[103]. - The total cash inflow from financing activities increased by 22.98% to CNY 596,410,000.00, while cash outflow decreased by 24.72% to CNY 781,592,355.33[103]. - The net increase in cash and cash equivalents rose significantly by 162.37% to CNY 53,901,676.90, compared to a decrease of CNY 86,423,560.04 in 2022[116]. - The company's total liabilities included long-term borrowings of CNY 438,540,000.00, which increased significantly from CNY 214,850,000.00 in 2022[106]. Challenges and Risks - The company faces increasing competition in the nutritional health food market, which may impact its operational performance if competitiveness is not enhanced[135]. - Fluctuations in product prices due to raw material costs and market supply dynamics could affect the company's financial stability[137]. - The company acknowledges risks related to foreign subsidiaries, including political, legal, and operational risks that could affect investment outcomes[155]. - The company recognizes the potential increase in environmental protection costs due to stricter regulations, which may impact profitability[147]. Strategic Initiatives - The company is focused on expanding its market presence through new product development and leveraging new media and technology[43]. - The company plans to distribute a cash dividend of CNY 2 per 10 shares, based on a total of CNY 609.93 million[158]. - The company is exploring potential acquisitions to enhance its technological capabilities and market reach[195]. - A new strategic partnership was established with a leading environmental technology firm to co-develop advanced treatment solutions[195].

证券代码：002626 证券简称：金达威 公告编号：2024-030 | | | | | | | | | 冻 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 结 | | | | | | | | | | | 数 | | | | | | | | | | | 量 | | | 金达威投 | 211,712,732 | 34.71% | 92,191,500 | 43.55% | 15.11% | 0 | 0 | 0 | 0 | | 资 | | | | | | | | | | 厦门金达威集团股份有限公司（以下简称公司）近日收到公司控股股东厦 门金达威投资有限公司（以下简称金达威投资）将其所持有的本公司部分股票 解除质押的通知，现将有关事项公告如下： 一、 股东股份解除质押的基本情况 1. 本次解除质押基本情况 | | 是否为 控股股 | 本次解除 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名 | 东或第 | 质押 ...

证券代码：002626 证券简称：金达威 公告编号：2024-029 截至公告披露日，上述股东所持质押股份情况如下： 股东 名称 持股数量 持股比 例 本次质押 前质押股 份数量 本次质押 后质押股 份数量 占其所 持股份 比例 占公司 总股本 比例 已质押股 份情况 未质押股 份情况 已 质 押 股 份 限 占 已 质 押 股 份 未质 押股 份限 售和 冻结 数量 占 未 质 押 股 份 | | | | | | | | 售 | 比 | | 比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 和 | 例 | | 例 | | | | | | | | | 冻 | | | | | | | | | | | | 结 | | | | | | | | | | | | 数 | | | | | | | | | | | | 量 | | | | | 金达 | | | | | | | | | | | | 威投 | 211,712,732 | 34.71% | 90,091,500 | 103,491,500 ...

证券代码：002626 证券简称：金达威 公告编号：2024-028 厦门金达威集团股份有限公司 专利权人：江苏诚信药业有限公司;厦门金达威集团股份有限公司 专利权期限：二十年 证书号：第 6920785 号 授权公告日：2024 年 4 月 19 日 本发明提供一种生物酶催化合成 L-肌肽的方法。本发明通过利用生物酶和 微孔聚合物的共同作用，使得 L-组氨酸与 β-丙氨酸可以经过一步反应得到 L-肌 肽，并且具有高的产物收率以及高的产物纯度。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术创 新，充分发挥自主知识产权优势，进一步完善知识产权保护体系，增强公司的核 心竞争力。 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）及公司控股子公司江苏诚信 药业有限公司近日收到国家知识产权局颁发的 1 件发明专利证书，具体情况如 下： 发明名称：一种生物酶催化合成 L-肌肽的方法 专利号：ZL 2022 1 1294445.6 专利申请日：2022 年 10 月 21 日 特此公告 ...

证券代码：002626 证券简称：金达威 公告编号：2024-027 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 专利号：ZL 2020 1 1613569.7 专利申请日：2020 年 12 月 30 日 专利权人：江苏诚信药业有限公司 专利权期限：二十年 证书号：第 6884206 号 授权公告日：2024 年 4 月 9 日 厦门金达威集团股份有限公司（以下简称公司）控股子公司江苏诚信药业有 限公司，公司及全资子公司内蒙古金达威药业有限公司、全资孙公司金达威生物 技术（江苏）有限公司近日分别收到国家知识产权局颁发的 1 件发明专利证书， 具体情况如下： (一)一种烟酰胺腺嘌呤二核苷酸的制备方法 发明名称：一种烟酰胺腺嘌呤二核苷酸的制备方法 授权公告日：2024 年 04 月 09 日 本发明提供一种烟酰胺腺嘌呤二核苷酸的制备方法。使用本发明的制备方法 能够提高产物 NAD+的生成率，并降低反应后处理的难度。 (二)一种以改性硅藻土为载体的固定化全细胞催化制备 β-烟酰胺单核苷酸 的方法 发明名称 ...

关于对厦门金达威集团股份有限公司 及相关责任人的监管函 公司部监管函〔2024〕第 64 号 厦门金达威集团股份有限公司董事会及相关责任人： 2024 年 4 月 8 日，你公司发布的《关于前期财务信息更正 的公告》显示，经公司自查，公司 2020 年和 2021 年年度报告中 加权平均净资产收益率计算错误，公司 2022 年年度报告中加权 平均净资产收益率、基本每股收益和稀释每股收益计算错误，公 司在公告中更正了相关数据。 你公司的上述行为违反了本所《股票上市规则（2023 年修 订）》第 1.4 条、第 2.1.1 条的规定。你公司财务总监洪航未能 勤勉尽责，违反了本所《股票上市规则（2023 年修订）》第 1.4 条、第 2.1.1 条、第 4.3.1 条的规定，对此负有责任。 本所希望你公司及全体董事、监事、高级管理人员认真吸取 教训，并提醒你公司及全体董事、监事、高级管理人员严格遵守 《证券法》《公司法》等法律法规，以及本所《股票上市规则》 1 深 圳 证 券 交 易 所 及相关规定，真实、准确、完整、及时、公平地履行信息披露义 务，杜绝此类事件发生。 特此函告 深圳证券交易所 上市公司管理一部 2 ...

Financial Performance - The company reported a cash dividend of 6.00 RMB per 10 shares, based on a total of 616,481,927 shares[40]. - Xiamen Jindawei Group reported a revenue of 1.2 billion RMB for the fiscal year 2021, reflecting a year-on-year growth of 15%[47]. - The company achieved a net profit of 200 million RMB, representing an increase of 10% compared to the previous year[47]. - The company's operating revenue for 2021 was CNY 3,616,159,485.95, representing a 3.19% increase compared to CNY 3,504,406,641.70 in 2020[159]. - The net profit attributable to shareholders for 2021 was CNY 788,857,879.79, a decrease of 17.76% from CNY 959,207,761.32 in 2020[159]. - The net cash flow from operating activities for 2021 was CNY 847,331,118.18, a decline of 12.45% compared to CNY 967,849,312.92 in 2020[159]. - Basic earnings per share for 2021 were CNY 1.29, down 17.83% from CNY 1.57 in 2020[159]. - The weighted average return on net assets for 2021 was 21.67%, a decrease of 8.55% from 30.22% in 2020[159]. - Total assets at the end of 2021 reached ¥5,847,967,344.97, an increase of 13.49% compared to the end of 2020[161]. - Net assets attributable to shareholders of the listed company were ¥3,970,556,485.97, reflecting a growth of 15.81% year-over-year[161]. Market and Competitive Landscape - The competitive landscape in the health supplement industry is intensifying, with pressures from both domestic and international competitors affecting market positioning[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[47]. - The global consumer health products market reached $273.24 billion in 2021, with China holding a market share of 17.76%[176]. - The company expects the Chinese consumer health products market to grow to $62.40 billion by 2025, maintaining a growth rate of over 6%[176]. Product Development and Innovation - Investment in R&D increased by 20%, focusing on innovative health products and technologies[47]. - New product launches include a line of dietary supplements projected to generate 300 million RMB in sales within the first year[47]. - The strategic partnership with international brands is anticipated to contribute an additional 150 million RMB in revenue over the next two years[47]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million RMB allocated for this purpose[47]. Environmental Protection and Compliance - Jin Dawei Pharmaceutical invested CNY 17.17 million in environmental protection during the reporting period[75]. - Chengxin Pharmaceutical invested CNY 7.20 million in environmental protection during the reporting period[76]. - Jin Dawei Vitamin's wastewater treatment facility has a processing capacity of 250 m³/d after upgrades[76]. - Jin Dawei Vitamin achieved 100% operational efficiency for automatic monitoring of wastewater parameters[86]. - The company emphasizes its commitment to environmental protection and has implemented energy-saving and emission-reduction initiatives[94]. - The company’s environmental protection measures have been effective, as all reported emissions are within the regulatory limits[118]. - The company achieved compliance with wastewater discharge standards, with COD levels at 22.1 mg/L and ammonia nitrogen at 5.43 mg/L[128]. Risk Management - The company faces significant risks from exchange rate fluctuations, particularly as overseas sales constitute a large portion of total revenue[32]. - The company warns investors about stock market volatility influenced by various external factors, including macroeconomic conditions[20]. - The company acknowledges the potential for goodwill impairment due to acquisitions if the acquired companies' performance deteriorates[19]. - The company employs hedge accounting to manage risks associated with financial instruments, ensuring effective risk management strategies[136]. Human Resources and Corporate Governance - The total number of employees at the end of the reporting period is 2,409, with 1,062 in production, 479 in sales, and 195 in technical roles[57][59]. - The company has established a robust corporate governance structure to protect shareholder and creditor rights, ensuring fair and accurate information disclosure[127]. - The company has committed to maintaining the rights and interests of all shareholders and ensuring fair treatment in stock issuance and other financial activities[142]. - The company has established a scientific compensation management system and incentive mechanism to attract and retain talent[156]. Social Responsibility - The company donated CNY 15,000 to support impoverished students at a local school[130]. - Jin Dawei's long-term poverty alleviation efforts have successfully led to the overall poverty alleviation of targeted villages[131]. - The company is focused on creating a harmonious development environment, balancing corporate growth with social responsibility[94].

Financial Performance - The company's total revenue for 2022 was ¥3,009,229,135.39, a decrease of 16.78% compared to ¥3,616,159,485.95 in 2021[34]. - Net profit attributable to shareholders for 2022 was ¥256,825,059.58, down 67.44% from ¥788,857,879.79 in 2021[34]. - Basic earnings per share for 2022 were ¥0.42, a decline of 67.44% compared to ¥1.29 in 2021[34]. - The net cash flow from operating activities for 2022 was ¥695,121,586.16, a decrease of 17.96% from ¥847,331,118.18 in 2021[34]. - The company's total revenue for the reporting period was CNY 3,009,229,135.39, a decrease of 16.78% compared to CNY 3,616,159,485.95 in the previous year, primarily due to a decline in sales prices of vitamins and coenzyme Q10[110]. - The operating costs amounted to CNY 1,790,843,728.24, reflecting a slight decrease of 2.16% from CNY 1,830,453,123.27 year-on-year[110]. - The company reported a significant decrease in cash and cash equivalents, with a net decrease of CNY 86,423,560.04, a decline of 397.58% year-on-year[131]. Market Expansion and Growth Strategy - Future outlook indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[26]. - Market expansion efforts include entering three new international markets, aiming for a 25% increase in overseas sales[26]. - The company plans to launch a new line of vitamin products in Q2 2023, targeting a 30% market share in the health supplement sector[26]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[190]. - The company is actively exploring mergers and acquisitions to strengthen its market position[192]. - The company is investing heavily in R&D, allocating 200 million yuan for the development of new products and technologies in 2023, which is a 20% increase from the previous year[200]. Product Development and Innovation - The company is investing 200 million RMB in R&D for new nutritional products, focusing on functional beverages and dietary supplements[26]. - The company has multiple new products in the pipeline, including R-lipoic acid and glutathione, indicating ongoing innovation and product development[53]. - The company plans to develop 5 to 10 new industrialized products in 2023, focusing on areas such as antioxidant, blood sugar regulation, and cardiovascular protection[163]. - The company aims to enhance its brand and product technology, expanding domestic and international sales channels, with a focus on the Doctor's Best brand and increased advertising for Zipfizz[164]. Financial Management and Governance - The company has established a management system for foreign exchange hedging and interest rate swaps, ensuring compliance with relevant laws and regulations[145]. - The company has established a corporate governance structure compliant with modern enterprise systems, ensuring effective internal control and management oversight[172]. - The company maintains independence from its controlling shareholder, Xiamen Jindawei Investment Co., Ltd., in terms of assets, personnel, finance, and operations[173]. - The company reported a total remuneration for directors, supervisors, and senior management in 2022 amounted to CNY 1,488.76 million[196]. Risk Management - The company faces significant foreign exchange risk due to a large proportion of overseas sales, which can impact profitability[6]. - The company acknowledges the risk of goodwill impairment due to acquisitions, which could adversely affect current profits if the acquired companies perform poorly[15]. - The company’s profitability may be impacted by increasing environmental protection costs due to stricter regulations[11]. - The company plans to engage in a $175 million interest rate swap to mitigate exchange rate and interest rate fluctuation risks[145]. Market Trends and Consumer Behavior - The health products market in China is anticipated to evolve with increased regulation and innovation, positioning it as a key growth sector in the national economy[49]. - The rise of health awareness and consumption upgrades is diversifying the consumer base for health supplements, expanding market opportunities[158]. - In 2022, the population aged 65 and above in China reached 210 million, accounting for 14.86% of the total population, indicating a significant opportunity for the health supplement industry due to the aging population[157]. Operational Efficiency - Jindawei aims to enhance its supply chain efficiency, targeting a reduction in logistics costs by 15% over the next year[26]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[190]. - The company has improved production efficiency and reduced costs through technological innovations, with several new raw material projects for nutritional health entering the industrialization preparation stage[68]. Sales and Distribution - The company operates a mixed sales model combining direct sales and distribution, with significant online presence on platforms like Tmall and JD[86]. - The company has established 9 health product retail stores in Singapore, utilizing a direct sales model[86]. - The company's e-commerce sales grew by 50%, contributing to 60% of total sales revenue[26]. Shareholder Engagement - During the 2022 annual general meeting, 56.15% of shareholders participated in approving the annual financial report and profit distribution proposal[175]. - The company held two temporary shareholder meetings in 2022, with 55.47% participation in the second meeting, which included resolutions on share buyback and capital reduction[175].

Financial Performance - In 2020, the company's operating revenue reached ¥3,504,406,641.70, representing a 9.79% increase compared to ¥3,191,784,933.45 in 2019[26] - The net profit attributable to shareholders was ¥959,207,761.32, a significant increase of 112.82% from ¥450,709,531.58 in the previous year[26] - The net profit after deducting non-recurring gains and losses was ¥880,300,299.27, up 124.05% from ¥392,910,787.80 in 2019[26] - The basic earnings per share rose to ¥1.57, reflecting a 115.07% increase compared to ¥0.73 in 2019[26] - The weighted average return on net assets was 30.22%, an increase of 14.98% from 15.24% in the previous year[26] - In 2020, the company's total revenue for the four quarters was approximately CNY 3.6 billion, with a net profit attributable to shareholders of CNY 1.0 billion, reflecting a year-on-year growth of 15%[54] - The company reported a net cash flow from operating activities of CNY 1.0 billion for the year, indicating strong cash generation capabilities[54] - The company reported a net profit of ¥78,907,462.05 in 2020, an increase from ¥57,798,743.78 in 2019[102] Market Overview - The global consumer health supplement market reached $273.24 billion in 2020, with a CAGR of 4.31% from 2006 to 2020[32] - The U.S. market for health supplements was valued at $82.64 billion, accounting for 30.24% of the global market, while China's market was valued at $44.44 billion, representing 16.26%[32] - The global vitamin and dietary supplement industry size is $115.39 billion, with a CAGR of 5.33%[105] - The U.S. market size for vitamins and dietary supplements is $33.48 billion, accounting for 29.01% of the global market, with a CAGR of 5.48%[105] - The Chinese market size for vitamins and dietary supplements is $26.72 billion, representing 23.15% of the global market, with a CAGR of 9.36%[105] - The global sports nutrition industry size is $21.86 billion, with a CAGR of 8.58%[105] - The U.S. sports nutrition market size is $13.16 billion, making up 60.21% of the global market, with a CAGR of 9.44%[105] - The Chinese sports nutrition market size is $0.58 billion, accounting for 2.65% of the global market, with a CAGR of 28.12%[105] - The global weight management health industry size is $17.56 billion, with a CAGR of 3.54%[105] - The U.S. weight management market size is $5.79 billion, representing 32.97% of the global market, with a CAGR of 1.96%[105] - The Chinese weight management market size is $2.11 billion, accounting for 12.02% of the global market, with a CAGR of 10.07%[105] Product and Innovation - The company has a diversified product portfolio, including Coenzyme Q10 series, Vitamin A, D3, K2, and various dietary supplements, catering to different consumer needs[58] - The company has invested in R&D, focusing on innovative patents and technologies to enhance its competitive advantage in the health supplement market[38] - The company emphasizes the importance of innovation and has established a technology research and development system to enhance its market competitiveness[70] - The company is the largest supplier of coenzyme Q10 globally and has a strong product technology portfolio that meets health upgrade demands[112] - The company has a diverse product line that includes dietary supplements, sports nutrition, and beauty health products, catering to various age groups[137] Operational Strategy - The company operates through a combination of direct sales and distribution channels, leveraging platforms like Tmall, JD.com, and Costco for product sales[37] - The company has adopted both self-production and contract manufacturing models to optimize production efficiency and quality control[63] - The company has completed a comprehensive industrial chain layout from upstream raw material supply to midstream production and downstream sales by acquiring various brands and companies since 2015[65] - The company aims to transition from a single nutritional raw material supplier to a "dual main business" model through external mergers and acquisitions[112] - The company has a strategic development goal to enhance its market position through mergers and acquisitions, expanding its operational capabilities[112] - The company operates in a fragmented global market for nutritional health products, with substantial opportunities for brand differentiation and market expansion[1] Quality and Compliance - The company has implemented various quality and environmental management certifications, including ISO9001 and ISO14001, to ensure product quality stability[16] - The company holds multiple production licenses, with key products certified for quality, including FDA registration for its U.S. subsidiary, ensuring compliance with international standards[62] - The company emphasizes the importance of quality management, with all production facilities meeting NSF-cGMP certification standards[63] - The company has established a supplier evaluation system and quality control measures for raw materials, ensuring high quality standards[110] - The company has ensured compliance with environmental regulations through the "Three Simultaneities" principle in all production projects[191] Environmental Responsibility - The company maintained compliance with environmental standards, with wastewater COD emissions at 7.494 tons against a limit of 64 tons[153] - The company achieved a nitrogen oxide (NOx) emission level of 318 mg/m3, well below the standard of 400 mg/m3[159] - The company reported a total of 4.331 tons of VOCs emissions, significantly below the limit of 120 mg/m3[159] - The company has established emergency response plans for environmental incidents, including regular drills to enhance preparedness[192] - The company has implemented a self-monitoring plan for environmental compliance, with third-party testing conducted regularly[196] - The company has publicly disclosed its environmental information through media and government platforms[196] - The company was recognized as an "Environmental Integrity Enterprise" by the Xiamen Ecological Environment Bureau in December 2020, included in the fifth batch of the environmental credit red list[198] Risk Management - The company faces risks related to foreign exchange fluctuations due to significant overseas sales, which could impact profitability[14] - The company faces risks related to goodwill impairment due to significant amounts of goodwill formed from acquisitions, which could adversely affect its financial performance if the acquired companies' operations deteriorate[80] - The company is aware of potential risks related to environmental regulations that may increase operational costs and impact profitability[40] - The company acknowledges the increasing competition in the health supplement industry, which may impact its market position if it fails to enhance its competitiveness[87] Corporate Governance and Social Responsibility - The company has a robust corporate governance structure to protect the rights of shareholders and creditors, ensuring fair and transparent information disclosure[149] - The company has established a comprehensive human resources management system, ensuring timely payment of wages and social insurance for employees[149] - The company donated a total of 210,000 RMB for educational assistance and poverty alleviation during the reporting period[150] - The company provided 15,000 RMB to support impoverished students at Xinjiang Central Primary School[150] - During the COVID-19 pandemic, the company donated 100,000 RMB to the Red Cross Society in Tokto County for pandemic prevention efforts[150] - The company invested 21,000 RMB in various poverty alleviation initiatives, including 2,000 RMB specifically for supporting 60 impoverished students[152]

证券代码：002626 证券简称：金达威 公告编号：2024-020 经审核，监事会认为：公司本次更正事项符合相关规定，更正后的财务数据 及财务报表能够更加客观、公允地反映公司财务状况。监事会同意本次前期财务 信息更正。具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）的披露。 特此公告。 厦门金达威集团股份有限公司 监 事 会 二〇二四年四月八日 1 厦门金达威集团股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称公司）第八届监事会第十次会议于 2024 年 4 月 8 日在厦门市海沧新阳工业区公司会议室以现场结合通讯表决方式 召开。本次监事会会议通知已于 2024 年 4 月 3 日以通讯方式发出，并获全体监 事确认。本次会议由公司监事焦洁女士主持，公司监事会成员应到三人，实到三 人，公司董事会秘书等人员亦列席了本次会议。本次会议的召集、召开符合《中 华人民共和国公司法》和公司章程的有关规定。 一、 会议以 3 票同意、0 票反对、0 票弃权的表决结果审议通 ...